CIPLA ICATIBANT icatibant (as acetate) 30 mg/3 mL solution for injection pre-filled syringe Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

cipla icatibant icatibant (as acetate) 30 mg/3 ml solution for injection pre-filled syringe

cipla australia pty ltd - icatibant acetate, quantity: 31.38 mg (equivalent: icatibant, qty 30 mg) - injection, solution - excipient ingredients: sodium chloride; glacial acetic acid; sodium hydroxide; water for injections - cipla icatibant is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older with c1-esterase-inhibitor deficiency.

GANIRELIX THERAMEX ganirelix (as acetate) 250 microgram/0.5 mL solution for injection prefilled syringe Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

ganirelix theramex ganirelix (as acetate) 250 microgram/0.5 ml solution for injection prefilled syringe

theramex australia pty ltd - ganirelix, quantity: 0.25 mg - injection, solution - excipient ingredients: glacial acetic acid; water for injections; mannitol; sodium hydroxide - for the prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation, followed by oocyte pick up and assisted reproductive techniques

ESMOLOL JUNO esmolol hydrochloride100 mg/10 mL solution for injection vial Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

esmolol juno esmolol hydrochloride100 mg/10 ml solution for injection vial

juno pharmaceuticals pty ltd - esmolol hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride; glacial acetic acid; sodium acetate trihydrate - supraventricular tachycardia,esmolol juno is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol juno is also indicated in non compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. esmolol juno is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

TECVAYLI teclistamab 10mg/mL solution for injection vial Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

tecvayli teclistamab 10mg/ml solution for injection vial

janssen-cilag pty ltd - teclistamab, quantity: 30 mg - injection, solution - excipient ingredients: glacial acetic acid; sucrose; disodium edetate; sodium acetate trihydrate; polysorbate 20; water for injections - tecvayli as monotherapy has provisional approval in australia and is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-cd38 monoclonal antibody.,the decision to approve this indication has been made on the basis of the overall response rate in a single arm study. continued approval of this indication depends on verification and description of benefit in confirmatory trials.

TECVAYLI teclistamab 90mg/mL solution for injection vial Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

tecvayli teclistamab 90mg/ml solution for injection vial

janssen-cilag pty ltd - teclistamab, quantity: 153 mg - injection, solution - excipient ingredients: polysorbate 20; sodium acetate trihydrate; glacial acetic acid; sucrose; water for injections; disodium edetate - tecvayli as monotherapy has provisional approval in australia and is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-cd38 monoclonal antibody.,the decision to approve this indication has been made on the basis of the overall response rate in a single arm study. continued approval of this indication depends on verification and description of benefit in confirmatory trials.

ESMOLOL HYDROCHLORIDE MEDSURGE esmolol hydrochloride 100 mg/10 mL solution for injection vial Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

esmolol hydrochloride medsurge esmolol hydrochloride 100 mg/10 ml solution for injection vial

medsurge pharma pty ltd - esmolol hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate trihydrate; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - esmolol hydrochloride medsurge is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol hydrochloride medsurge is also indicated in non-compensatory sinus tachycardia where, in the physician?s judgement, the rapid heart rate requires specific intervention. esmolol hydrochloride medsurge is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

Duratocin Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

duratocin

pharmaco (nz) ltd - carbetocin 100ug; carbetocin 100 µg/ml - solution for injection - 100 mcg - active: carbetocin 100ug excipient: glacial acetic acid sodium chloride water for injection active: carbetocin 100 µg/ml excipient: mannitol methionine sodium hydroxide succinic acid water for injection - duratocin is indicated for the prevention of uterine atony and excessive bleeding following delivery of the infant by elective caesarean section under epidural or spinal anaesthesia.

TROPISETRON MYX tropisetron (as hydrochloride) 2 mg/2 mL solution for injection or infusion ampoules Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

tropisetron myx tropisetron (as hydrochloride) 2 mg/2 ml solution for injection or infusion ampoules

juno pharmaceuticals pty ltd - tropisetron hydrochloride, quantity: 2.26 mg (equivalent: tropisetron, qty 2 mg) - injection, solution - excipient ingredients: sodium chloride; water for injections; glacial acetic acid; sodium acetate trihydrate - for the treatment and prevention of post-operative nausea and vomiting in adults (2 mg/2 ml ampoule only)

CIPROXIN HC EAR DROPS 0.2% ciprofloxacin (as      hydrochloride) and 1% hydrocortisone ear drops Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

ciproxin hc ear drops 0.2% ciprofloxacin (as hydrochloride) and 1% hydrocortisone ear drops

novartis pharmaceuticals australia pty ltd - ciprofloxacin, quantity: 2 mg/ml; hydrocortisone, quantity: 10 mg/ml - ear drops, suspension - excipient ingredients: polysorbate 20; sodium acetate; glacial acetic acid; benzyl alcohol; hydrogenated soy phosphatidylcholine; sodium chloride; polyvinyl alcohol; purified water - for the treatment of acute bacterial otitis externa, caused by organisms susceptible to ciprofloxacin (see pharmacology), in adults and children aged 2 years and older.

Aquaear Ear Drops solution bottle Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

aquaear ear drops solution bottle

haleon australia pty ltd - isopropyl alcohol, quantity: 634 mg/ml; glacial acetic acid, quantity: 17.3 mg/ml - ear drops, solution - excipient ingredients: purified water - helps prevent and helps treat swimmer's ear the painful ear infection that often occurs when water is trapped in the ear canal after swimming, bathing, surfing or diving. aquaear dries up moisture and retards the growth of bacteria. aquaear also helps relieve the painful inflammation caused by swimmer's ear.